HomePHIO • NASDAQ
add
Phio Pharmaceuticals Corp
Nakaraang pagsara
$1.17
Sakop ng araw
$1.19 - $1.22
Sakop ng taon
$0.81 - $4.19
Market cap
13.94M USD
Average na Volume
7.43M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 1.06M | 53.41% |
Net na kita | -2.37M | -45.82% |
Net profit margin | — | — |
Kita sa bawat share | -0.15 | — |
EBITDA | -2.53M | -51.31% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 21.03M | 290.77% |
Kabuuang asset | 21.49M | 274.47% |
Kabuuang sagutin | 1.34M | 32.02% |
Kabuuang equity | 20.15M | — |
Natitirang share | 11.62M | — |
Presyo para makapag-book | 0.68 | — |
Return on assets | -38.40% | — |
Return on capital | -42.25% | — |
Cash Flow
Net change in cash
| (USD) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -2.37M | -45.82% |
Cash mula sa mga operasyon | -2.08M | -51.64% |
Cash mula sa pag-invest | 0.00 | -100.00% |
Cash mula sa financing | 12.40M | 815.50% |
Net change in cash | 10.33M | 129,175.00% |
Malayang cash flow | -1.29M | -64.92% |
Tungkol
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Wikipedia
Itinatag
2011
Website
Mga Empleyado
6
